Cancer metastasis and resistance to therapy pose significant clinical challenges and are major contributors to cancer-related deaths worldwide.
Numerous studies have implicated disrupted transcriptional programs in driving tumor aggressiveness.
Research within the Cancer team in the Genome Biology unit focuses on unraveling the mechanisms underlying cancer metastasis and therapy resistance.
We leverage this knowledge to discover robust biomarkers for patient stratification towards precision medicine and to identify new, effective therapeutic targets for improved clinical outcomes.
To achieve these goals, we employ an integrative approach combining single-cell multi-omics, epigenomics, spatial transcriptomics, computational biology, and machine learning. We utilize established in vitro cellular systems, mouse models, patient-derived xenografts, and patient samples.
Our research involves close collaboration between basic researchers and clinicians, facilitating the clinical translation of our findings and ultimately aiming to enhance human health through innovative, multidisciplinary research.
